PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
176.45 - 178.59
86.62 - 184.48
124.91M / 173.95M (Avg.)
50.81 | 3.50
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
7.81%
Revenue growth above 1.5x AVGO's 1.82%. David Dodd would confirm if the firm has a unique advantage driving sales higher.
6.60%
Positive gross profit growth while AVGO is negative. John Neff would see a clear operational edge over the competitor.
5.91%
Positive EBIT growth while AVGO is negative. John Neff might see a substantial edge in operational management.
5.91%
Positive operating income growth while AVGO is negative. John Neff might view this as a competitive edge in operations.
9.05%
Positive net income growth while AVGO is negative. John Neff might see a big relative performance advantage.
9.09%
Positive EPS growth while AVGO is negative. John Neff might see a significant comparative advantage in per-share earnings dynamics.
26.32%
Positive diluted EPS growth while AVGO is negative. John Neff might view this as a strong relative advantage in controlling dilution.
No Data
No Data available this quarter, please select a different quarter.
-9.46%
Reduced diluted shares while AVGO is at 0.00%. Joel Greenblatt would see a relative advantage if the competitor is diluting more.
No Data
No Data available this quarter, please select a different quarter.
-33.58%
Negative OCF growth while AVGO is at 90.00%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
-44.88%
Negative FCF growth while AVGO is at 134.15%. Joel Greenblatt would demand improved cost control or more strategic capex discipline.
660.55%
10Y CAGR of 660.55% while AVGO is zero. Bruce Berkowitz would see if incremental growth can widen into a significant edge.
132.27%
5Y CAGR of 132.27% while AVGO is zero. Bruce Berkowitz would see if small improvements can scale into a larger advantage.
103.68%
3Y CAGR of 103.68% while AVGO is zero. Bruce Berkowitz would see if small gains can accelerate to a more decisive lead.
3767.77%
OCF/share CAGR of 3767.77% while AVGO is zero. Bruce Berkowitz might see a slight advantage that could compound over time.
83.91%
OCF/share CAGR of 83.91% while AVGO is zero. Bruce Berkowitz would see if modest momentum can translate into a bigger competitive lead.
144.23%
3Y OCF/share CAGR of 144.23% while AVGO is zero. Bruce Berkowitz might see if small gains can expand into a broader advantage.
1329.20%
10Y net income/share CAGR of 1329.20% while AVGO is zero. Bruce Berkowitz would see if minor gains can compound into a bigger lead over time.
356.93%
Net income/share CAGR of 356.93% while AVGO is zero. Bruce Berkowitz would see if small mid-term gains can develop into a bigger lead.
413.54%
3Y net income/share CAGR of 413.54% while AVGO is zero. Bruce Berkowitz sees if minor improvements can widen to a bigger advantage.
1605.93%
Equity/share CAGR of 1605.93% while AVGO is zero. Bruce Berkowitz might see a slight advantage that can compound significantly over 10 years.
154.20%
Equity/share CAGR of 154.20% while AVGO is zero. Bruce Berkowitz might see a minor advantage that could compound if the firm maintains positive net worth growth.
113.15%
Equity/share CAGR of 113.15% while AVGO is zero. Bruce Berkowitz sees if minor gains can snowball into a bigger lead soon.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
20.65%
AR growth of 20.65% while AVGO is zero. Bruce Berkowitz wonders if the firm’s additional AR is warranted by strong revenue or potential risk.
17.11%
Inventory growth of 17.11% while AVGO is zero. Bruce Berkowitz wonders if we anticipate a new wave of demand or risk being stuck with extra product.
7.84%
Asset growth of 7.84% while AVGO is zero. Bruce Berkowitz checks if modest expansions can create a longer-term lead.
5.65%
BV/share growth of 5.65% while AVGO is zero. Bruce Berkowitz sees if small growth can compound into a strong advantage.
No Data
No Data available this quarter, please select a different quarter.
9.08%
R&D growth drastically higher vs. AVGO's 1.47%. Michael Burry fears near-term margin erosion unless breakthroughs are imminent.
3.49%
We expand SG&A while AVGO cuts. John Neff might see the competitor as more cost-optimized unless we expect big payoffs from the overhead growth.